Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05201404 | Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis | PHASE3 | RECRUITING | 471 | — | — | Mar 15, 2023 | Oct 1, 2026 | Apr 29, 2025 | 32 | United States, Bosnia and Herzegovina +7 |
Median duration of survival
| Arm | Type | Description |
|---|---|---|
| Namodenoson (CF102) | EXPERIMENTAL | Namodenoson 25 mg orally BID, until disease progression or unacceptable adverse events |
| Placebo | PLACEBO_COMPARATOR | Matching placebo orally BID, until disease progression or unacceptable adverse events |
| Name | Type | Description |
|---|---|---|
| Namodenoson | DRUG | Adenosine A3 Receptor (A3AR) agonist |
| Placebo | DRUG | Control arm |
Inclusion Criteria: 1. Males and females at least 18 years of age. 2. Diagnosis of HCC: * For patients without cirrhosis at the time of diagnosis, histologic confirmation is required (archival tissue is acceptable). * For patients with underlying cirrhosis at the time of diagnosis, diagnosis...